10-Q: Lifeward Q2 2025: Losses Widen, Cash Dwindles Amid Capital Raises

Lifeward Ltd. reported increased net losses and a going concern warning for Q2 2025, despite significant capital raises and strategic product advancements.

Summary

• Net loss for the six months ended June 30, 2025, increased to $11.4 million, up from $10.6 million in the same period of 2024.
• Revenues decreased by 10.3% to $10.8 million for the six months ended June 30, 2025, compared to $12.0 million in the prior year, primarily due to elevated Medicare-related revenue in H1 2024 and lower MyoCycle sales.
• Gross profit increased to $4.6 million (43.1% of revenue) for the six months ended June 30, 2025, from $4.2 million (34.6% of revenue) in 2024, driven by lower production costs and manufacturing transitions.
• Operating expenses rose to $16.0 million from $15.1 million, largely due to a $2.8 million goodwill impairment charge in Q2 2025.
• Cash and cash equivalents stood at $5.1 million as of June 30, 2025, down from $6.7 million at December 31, 2024.
• Net cash used in operating activities improved significantly to $9.4 million for the six months ended June 30, 2025, compared to $13.3 million in the prior year, attributed to improved working capital management and reduced operating expenses.
• The company raised $7.8 million in net cash from financing activities during the first six months of 2025 through a registered direct offering, an at-the-market (ATM) program, and a public offering.
• Management concluded that there is substantial doubt about the company's ability to continue as a going concern, with existing cash expected to fund operations only into the fourth quarter of 2025.
• Lifeward received a Nasdaq deficiency letter on August 5, 2025, for failing to maintain a minimum bid price of $1.00 per share, facing potential delisting if compliance is not regained by February 2, 2026.
• The ReWalk 7, the latest exoskeleton model, received FDA clearance and launched in the U.S. in April 2025, with over 20 units installed to date.
• An Administrative Law Judge (ALJ) ruling in June 2025 established a legal basis for Medicare coverage and reimbursement of the ReWalk Personal Exoskeleton as a reasonable and necessary medical device.

Sentiment

Score: 3

Explanation: The sentiment is negative due to widening net and operating losses, declining revenue, a significant goodwill impairment, and a 'going concern' warning. The Nasdaq delisting notice adds substantial risk. While recent capital raises provide a temporary lifeline and operational improvements like reduced cash burn and new product launches are positive, they are overshadowed by the fundamental financial instability and the ongoing need for external funding.

Positives

• Net cash used in operating activities significantly improved to $9.4 million for the six months ended June 30, 2025, a 29.1% decrease from $13.3 million in the prior year, reflecting better working capital management and cost reductions.
• Gross profit margin increased to 43.1% for the six months ended June 30, 2025, up from 34.6% in the same period of 2024, driven by lower production costs following facility consolidation and manufacturing transitions.
• Successfully transitioned ReWalk product manufacturing in-house during Q2 2025, terminating the agreement with Sanmina, which is expected to yield cost savings, improved quality control, and greater production flexibility.
• Achieved FDA clearance and launched the ReWalk 7, the latest exoskeleton model, in the U.S. in April 2025, with positive customer feedback and over 20 units installed.
• An Administrative Law Judge (ALJ) ruling in June 2025 established a legal basis for Medicare coverage and reimbursement of the ReWalk Personal Exoskeleton, affirming its medical necessity.
• Expanded U.S. payer base for the ReWalk Personal Exoskeleton, including a new partnership with CorLife, LLC (a division of Numotion) for workers' compensation claims, which has already facilitated the first paid claim.
• Research and development expenses decreased by 32.5% to $1.7 million for the six months ended June 30, 2025, due to the completion of development programs for ReWalk 7 and AlterG NEO.
• Strengthened executive leadership with the appointment of Mark Grant as President and CEO and Almog Adar as CFO.

Negatives

• Reported a net loss of $11.4 million for the six months ended June 30, 2025, an increase from $10.6 million in the prior year period.
• Operating loss increased to $11.4 million for the six months ended June 30, 2025, compared to $10.9 million in the same period of 2024.
• Revenues decreased by 10.3% to $10.8 million for the six months ended June 30, 2025, primarily due to a one-time Medicare-related revenue recognized in H1 2024 and lower MyoCycle sales volume.
• Incurred a goodwill impairment charge of $2.8 million in the second quarter of 2025 due to a sustained decline in the company's stock price, indicating its market capitalization was below carrying value.
• Cash and cash equivalents declined to $5.1 million as of June 30, 2025, from $6.7 million at December 31, 2024.
• Management expressed substantial doubt about the company's ability to continue as a going concern, estimating existing cash will only fund operations into the fourth quarter of 2025.
• Received a Nasdaq deficiency letter on August 5, 2025, for non-compliance with the minimum $1.00 bid price requirement, posing a risk of delisting if compliance is not regained by February 2, 2026.
• General and administrative expenses increased by 24.3% to $4.0 million for the six months ended June 30, 2025, partly due to a $0.6 million bad debt expense related to Medicare claims and restructuring costs.

Risks

• Substantial doubt exists regarding the ability to continue as a going concern, as current cash resources are estimated to fund operations only into the fourth quarter of 2025, necessitating additional funding.
• Failure to regain and maintain compliance with Nasdaq's minimum bid price requirement could lead to delisting of ordinary shares, impairing liquidity and value.
• Difficulties may arise in transitioning the manufacturing of ReWalk products to in-house operations, including identifying and recruiting experienced teams and establishing new supplier agreements for components.
• The company's ability to achieve reimbursement from third-party payors, including Medicare, for its products is critical for future growth and financial stability.
• Market and other conditions, including inflationary pressures, interest rate and currency rate fluctuations, and global instability (e.g., Russia-Ukraine conflict, Middle East conflict, China-Taiwan tensions), could disrupt business operations or financial condition.
• The company relies on third-party suppliers for certain components and contract manufacturers for production, posing risks if these relationships are disrupted or costs increase.
• Compliance with medical device reporting regulations for adverse events could result in corrective actions or enforcement actions, impacting product marketing and sales.
• Risk of cybersecurity attacks or incidents significantly disrupting information technology systems and business operations.
• Inability to maintain adequate protection of intellectual property and avoid violation of others' intellectual property rights.
• Substantial sales of shares by certain shareholders could negatively impact the market price of ordinary shares.

Future Outlook

The company expects future growth to be driven by increased sales of the ReWalk Personal Exoskeleton through expanded commercial and government third-party payor coverage, greater penetration of AlterG Anti-Gravity systems in rehabilitation clinics globally, and more placements of the MyoCycle device. Research and development efforts will focus on supporting current products and reducing material costs for ReWalk and AlterG lines. The ReBoot personal soft exo-suit development remains on hold pending determination of its clinical and commercial opportunity. The company anticipates continued operating losses and negative operating cash flows, requiring additional funding to support planned operations beyond Q4 2025.

Management Comments

• Achieved FDA clearance and subsequent U.S. launch in April 2025 for the ReWalk 7, the latest innovation in the ReWalk pipeline, with over 20 ReWalk 7 units installed to date with overwhelmingly positive feedback from customers.
• Expanded and advanced the pipeline of qualified leads for the ReWalk and achieved the highest quarterly total of ReWalk units placed for Medicare beneficiaries since fee schedule established in April 2024.
• Continued expansion of U.S. payer base for the ReWalk Personal Exoskeleton, with a ruling by an Administrative Law Judge establishing a legal basis for medical necessity and the partnership with CorLife facilitating and accelerating processing for workers' compensation claims.
• Improved quarterly cash burn to $3.9 million, down from $5.6 million in Q2 2024 and $5.5 million in Q1 2025, driven by operational efficiencies, facility consolidations, and other cost reduction initiatives.
• Successfully transitioned to in-house manufacturing of the ReWalk Personal Exoskeleton during Q2, concluding the company's agreement with Sanmina and delivering cost savings, improved quality control, and greater production flexibility.
• Strengthened the company's executive leadership with the appointment of Mark Grant as Lifeward's President and CEO and Almog Adar as Lifeward's CFO to bolster the company's strategic initiatives toward sustainable growth.

Industry Context

Lifeward operates in the medical device industry, specializing in physical rehabilitation and recovery solutions, including robotic exoskeletons and anti-gravity systems. The company's focus on expanding Medicare and other third-party payor coverage for its ReWalk Personal Exoskeleton aligns with a broader industry trend of seeking reimbursement pathways for innovative, high-cost medical technologies. The acquisition of AlterG and distribution agreements for MyoCycle reflect a strategy to diversify product offerings and expand market reach within the rehabilitation continuum of care. The shift to in-house manufacturing for ReWalk products and the use of contract manufacturers for AlterG products indicate efforts to optimize supply chains and cost structures, a common practice in the medical device sector to improve margins and control quality.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess Lifeward's performance against global benchmarks. The analysis is based solely on the company's internal financial and operational data.

Management Changes

Corporate Governance

Legal Proceedings

• No material changes to legal proceedings were reported, except as described in Note 7 (Shareholders Equity) which details the recent capital raising activities and warrant issuances.

Related Party Transactions

• The filing details several equity raises involving 'certain institutional investors' and 'placement agents' (H.C. Wainwright & Co., LLC) for the issuance of ordinary shares and warrants. These transactions are part of the company's financing activities rather than typical operational related-party dealings.

Stakeholder Impact

• Shareholders: Face significant dilution from recent equity offerings, increased net losses, and the risk of delisting from Nasdaq, which could severely impact share price and liquidity.
• Employees: Subject to cost reduction initiatives, facility consolidations, and manufacturing transitions, which may involve restructuring costs and potential job impacts.
• Customers: Benefit from the launch of new products like the ReWalk 7 and expanded reimbursement pathways, particularly through Medicare and new distribution agreements like CorLife, potentially increasing access to devices.
• Creditors: The 'going concern' warning indicates increased risk for creditors, as the company's ability to meet its obligations is dependent on future capital raises.

Next Steps

• Regain compliance with Nasdaq's minimum bid price requirement by February 2, 2026, to avoid delisting.
• Secure additional funding to finance operations beyond the fourth quarter of 2025.
• Continue efforts to expand coverage and reimbursement for the ReWalk Personal Exoskeleton by commercial and government third-party payors.
• Drive sales growth for the AlterG Anti-Gravity system through greater penetration of rehabilitation clinics.
• Focus research and development resources on supporting current products and making design enhancements to reduce material costs for ReWalk and AlterG product lines.
• Evaluate the clinical and commercial opportunity for the ReBoot personal soft exo-suit, which is currently on hold.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by widening net losses, a substantial accumulated deficit, and a 'going concern' warning, indicating a high probability of needing further capital raises to sustain operations beyond Q4 2025. The Nasdaq delisting notice for failing to meet the minimum bid price adds significant uncertainty and could severely impair liquidity and shareholder value. While recent capital raises provide temporary relief and operational improvements like reduced cash burn and new product launches are positive, these are overshadowed by the fundamental financial instability and the continuous need for external funding, which will likely lead to further dilution. The overall risk profile is high, suggesting a 'sell' recommendation for investors.

Keywords

Lifeward, LFWD, Exoskeleton, Rehabilitation, Medical Device, Spinal Cord Injury, Stroke, Medicare, Nasdaq, Capital Raise, Financial Results, Going Concern, SEC Filing, 10-Q